Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov(Ministry of Health of the Russian Federation), Gintsburg Al(Gamalei Institute of Epidemiology and Microbiology)
Cited by 1,829
Related Papers
Circular mRNA against CleanCap linear mRNA vectors: comprehensive comparison, expression, active and passive immunization
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0